Adma Biologics ADMA Cash Flow Statement (2011-2026)

NASDAQ ADMA
$9.53 -0.05 (-0.52%)
As of: Sep 4, 2026 · 12:49 PM EDT
Reported Financials

Adma Biologics Quarterly Cash Flow Statement

Periods 53 quarters
Latest Jun 2026

Adma Biologics reported cash from operations of $29.54M and free cash flow of $27.28M for the quarter ended Jun 2026, up 39.7% year over year. This cash flow statement covers 53 quarters of results from Mar 2011 through Jun 2026, standardized by Business Quant from the company’s SEC filings.

Cash Flow Statement Mar2011 Jun2011 Sep2011 Dec2011 Mar2012 Jun2012 Sep2012 Dec2012 Mar2013 Dec2014 Dec2015 Mar2016 Jun2016 Sep2016 Dec2016 Mar2017 Jun2017 Sep2017 Dec2017 Mar2018 Jun2018 Sep2018 Dec2018 Mar2019 Jun2019 Sep2019 Dec2019 Mar2020 Jun2020 Sep2020 Dec2020 Mar2021 Jun2021 Sep2021 Dec2021 Mar2022 Jun2022 Sep2022 Dec2022 Mar2023 Jun2023 Sep2023 Dec2023 Mar2024 Jun2024 Sep2024 Dec2024 Mar2025 Jun2025 Sep2025 Dec2025 Mar2026 Jun2026
Operating Activities
Net Income
-17.73M-16.50M-18.17M-13.75M-14.89M-11.79M-6.79M-6.37M2.56M-11.71M17.81M32.06M35.91M111.90M26.90M34.22M36.43M46.75M45.33M37.82M
Share-based CompensationStock Comp.
7.83M1.21M8.69M8.50M8.33M1.07M9.95M9.64M5.84M1.75M6.42M6.52M5.97M5.43M5.86M5.50M5.23M5.39M6.33M6.13M
Deferred Taxes
84.28M3.42M1.62M4.80M-20.87M3.29M0.00M
Cash from OperationsCash from Ops.
-13.41M-33.47M-26.01M-12.83M-13.28M-7.38M-14.72M-6.06M11.98M17.60M-2.22M45.65M25.03M50.22M-19.68M21.14M13.29M35.64M58.25M29.54M
Depreciation, Depletion & Amortization
Amortizatization of IntangiblesAmort. of Intangibles
0.49M0.50M0.58M0.34M0.98M0.49M0.49M0.69M0.72M0.70M0.25M0.23M0.25M0.22M0.19M0.16M0.17M0.20M0.19M0.19M
Amortization of Deferred ChargesAmort. Deferred Charges
Depreciation & Amortization (CF)Dep. & Amort.
1.42M1.52M1.59M1.72M1.86M1.94M2.03M2.10M2.09M2.11M2.11M2.05M1.94M1.94M1.97M2.06M2.02M2.05M1.84M1.78M
Change in Working Capital
Change in ReceivablesChange Receivables
-3.15M8.18M-2.95M-6.75M2.02M-5.40M11.01M10.21M-5.41M-3.90M22.20M-19.51M20.03M-0.14M49.41M10.31M27.95M20.76M-22.57M2.37M
Change in InventoryChange Inventory
14.42M10.60M14.42M6.93M16.84M0.37M0.70M-2.21M1.34M9.79M4.83M2.08M-8.01M-1.57M1.95M19.28M5.20M9.80M15.63M17.21M
Change in Account PayablesChange Payables
11.12M-4.85M1.69M-2.73M13.81M-11.97M-0.27M-0.87M-0.01M4.99M0.45M-1.86M1.62M3.94M0.14M9.27M-4.88M-2.20M-1.23M10.08M
Change in Accured ExpensesChange Accured Exp.
2.55M2.81M-1.78M0.31M2.13M6.87M-1.35M6.09M0.14M2.66M0.77M-5.96M-0.19M4.24M-2.40M-2.81M-0.22M10.64M5.11M-6.58M
Investing Activities
Capital ExpendituresCapex
2.79M3.68M2.84M3.94M3.38M3.75M1.95M0.87M0.76M1.20M2.35M2.07M1.06M2.76M4.70M2.42M14.37M1.08M2.54M2.26M
Sales of Property, Plant and EquipmentPP&E (Sale)
5.00M
Change in Acquisitions & DivestmentsChange Acquisitions
Cash from Investing ActivitiesCash from Investing
-2.79M-3.68M-2.84M-3.94M-3.38M-3.75M-1.95M-0.87M-0.76M-1.41M-2.36M-2.37M-1.10M-2.75M-4.72M-2.53M-14.37M-0.28M2.40M-2.26M
Financing Activities
Other financing activitiesOther financing
2.38M0.40M72.000.47M0.62M1.25M1.03M0.33M5.69M0.44M0.10M2.06M0.39M0.43M0.59M0.04M
Cash from Financing ActivitiesCash from Financing
8.20M53.82M47.27M-0.32M-0.84M62.74M-0.65M0.24M0.42M-38.99M-1.45M-0.36M-25.47M-31.03M-7.13M0.05M-27.82M-9.12M-10.13M-29.42M
Change in Capital Stock
Net Shares Issued and RepurchasedNet Shares Issued
1.90M1.19M1.19M1.73M0.40M1.10M0.30M0.09M0.67M0.15M
Net Equity Issued and RepurchasedNet Equity Issued
8.21M53.83M64.64M
Additional items
Change in Cash
-8.00M16.68M18.42M-17.09M-17.51M51.62M-17.32M-6.69M11.64M-22.80M-6.03M42.92M-1.54M16.44M-31.52M18.66M-28.90M26.25M50.52M-2.13M
Free Cash FlowFCF
-16.20M-37.14M-28.86M-16.77M-16.67M-11.13M-16.67M-6.93M11.23M16.40M-4.57M43.58M23.97M47.46M-24.38M18.72M-1.07M34.55M55.71M27.28M
Net Cash FlowNCF
-8.00M16.68M18.42M-17.09M-17.51M51.62M-17.32M-6.69M11.64M-22.80M-6.03M42.92M-1.54M16.44M-31.52M18.66M-28.90M26.25M50.52M-2.13M